At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIAF bioAffinity Technologies, Inc.
Pre-Market Trading 12-23 08:56:52 EST
0.9928
-0.1872
-15.86%
盘前1.08
+0.0872+8.78%
08:19 EST
High1.29Low0.9820Vol478.85K
Open1.24D1 Closing1.18Amplitude26.10%
Mkt Cap15.47MTradable Cap8.65MTotal Shares15.58M
T/O515.19KT/O Rate5.50%Tradable Shares8.71M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
bioAffinity Technologies Boosts Sales with CyPath Lung
TipRanks  ·  12-21 19:33
bioAffinity Technologies Boosts Sales with CyPath Lung
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
Business Wire  ·  12-17
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
bioAffinity Technologies Set for Continued Expansion in 2025
Business Wire  ·  12-12
bioAffinity Technologies Set for Continued Expansion in 2025
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
Business Wire  ·  12-05
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
bioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States
Benzinga  ·  11-14
bioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
THOMSON REUTERS  ·  11-14
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
bioAffinity Technologies Inc Qtrly EPS $-0.16
THOMSON REUTERS  ·  11-14
bioAffinity Technologies Inc Qtrly EPS $-0.16
Press Release: bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
Dow Jones  ·  11-14
Press Release: bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
BRIEF-BioAffinity Technologies Appoints New Chief Science Officer To Spearhead Product Development
Reuters  ·  11-04
BRIEF-BioAffinity Technologies Appoints New Chief Science Officer To Spearhead Product Development
BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer
TIPRANKS  ·  11-04
BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
THOMSON REUTERS  ·  11-04
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
Business Wire  ·  11-04
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
bioAffinity Technologies Secures Japanese Patent for Lung Cancer Diagnostic Method
MT Newswires Live  ·  10-30
bioAffinity Technologies Secures Japanese Patent for Lung Cancer Diagnostic Method
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
Business Wire  ·  10-30
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
BioAffinity Technologies announces closing of $2.6M registered direct offering
TIPRANKS  ·  10-22
BioAffinity Technologies announces closing of $2.6M registered direct offering
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
THOMSON REUTERS  ·  10-21
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
PR Newswire  ·  10-21
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
THOMSON REUTERS  ·  10-21
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
Wallachbeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
THOMSON REUTERS  ·  10-19
Wallachbeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
BioAffinity Technologies Down 25% on Stock Sale, Warrant Private Placement
Dow Jones  ·  10-19
BioAffinity Technologies Down 25% on Stock Sale, Warrant Private Placement

Introduction

Company Name.
bioAffinity Technologies, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Issue price:
--